Ex­clu­sive: BioN­Tech ac­quires lipid nanopar­ti­cle start­up found­ed by George Ma­son and UPenn sci­en­tists

BioN­Tech, the Ger­man drug com­pa­ny fa­mous for de­vel­op­ing a Covid-19 vac­cine with Pfiz­er, has ac­quired Aex­eR­NA and its nov­el lipid nanopar­ti­cles for mR­NA med­i­cines, End­points News has learned.

Aex­eR­NA is a tiny start­up that large­ly ex­ists on pa­per. It has no lab or staff sci­en­tists, just a for­mer patent lawyer as its CEO and sev­er­al sci­en­tif­ic co-founders, in­clud­ing mR­NA pi­o­neer and re­cent No­bel Prize lau­re­ate Drew Weiss­man from the Uni­ver­si­ty of Penn­syl­va­nia, and bio­engi­neer Michael Buschmann of George Ma­son Uni­ver­si­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER